title: Poly-cyclodextrin functionalized porous bioceramics for local chemotherapy and anticancer bone reconstruction.
abstract: The progress in bone cancer surgery and multimodal treatment concept achieve only modest improvement in the overall survival, due to failure in clearing out residual cancer cells at the surgical margin and extreme side-effects of adjuvant postoperative treatments. Our study aims to propose a new method based on cyclodextrin polymer (polyCD) functionalized hydroxyapatite (HA) for achieving a high local drug concentration with a sustained release profile and a better control of residual malignant cells via local drug delivery and promotion of the reconstruction of bone defects. PolyCD, a versatile carrier for therapeutic molecules, can be incorporated into HA (bone regeneration scaffold) through thermal treatment. The parameters of polyCD treatment on the macroporous HA (porosity 65%) were characterized via thermogravimetric analysis. Good cytocompatibility of polyCD functionalized bioceramics was demonstrated on osteoblast cells by cell vitality assay. An antibiotic (gentamicin) and an anticancer agent (cisplatin) were respectively loaded on polyCD functionalized bioceramics for drug release test. The results show that polyCD functionalization leads to significantly improved drug loading quantity (30% more concerning gentamicin and twice more for cisplatin) and drug release duration (7 days longer concerning gentamicin and 3 days longer for cisplatin). Conclusively, this study offers a safe and reliable drug delivery system for bioceramic matrices, which can load anticancer agents (or/and antibiotics) to reduce local recurrence (or/and infection).
authors.affiliation: Université Lille Nord de France, Lille, France; Groupe de Recherche sur les Biomatériaux (U 1008 INSERM) Université Lille 2-Faculté de Médecine, Lille, France.
authors.forename: Feng
authors.initials: F
authors.lastname: Chai
authors.forename: Mohamed
authors.initials: M
authors.lastname: Abdelkarim
authors.forename: Thomas
authors.initials: T
authors.lastname: Laurent
authors.forename: Nicolas
authors.initials: N
authors.lastname: Tabary
authors.forename: Stephanie
authors.initials: S
authors.lastname: Degoutin
authors.forename: Nicolas
authors.initials: N
authors.lastname: Simon
authors.forename: Fabian
authors.initials: F
authors.lastname: Peters
authors.forename: Nicolas
authors.initials: N
authors.lastname: Blanchemain
authors.forename: Bernard
authors.initials: B
authors.lastname: Martel
authors.forename: Hartmut F
authors.initials: HF
authors.lastname: Hildebrand
mesh_terms: D000818:Animals; D001859:Bone Neoplasms / Q000628:therapy*; D018786:Bone Substitutes / Q000737:chemistry / Q000494:pharmacology*; D002460:Cell Line; D002516:Ceramics / Q000737:chemistry / Q000493:pharmacokinetics*; D003505:Cyclodextrins / Q000737:chemistry / Q000494:pharmacology*; D016503:Drug Delivery Systems; D017886:Durapatite / Q000737:chemistry / Q000494:pharmacology; D008422:Materials Testing / Q000379:methods; D051379:Mice; D010006:Osteoblasts / Q000378:metabolism / Q000473:pathology; D011108:Polymers / Q000737:chemistry / Q000494:pharmacology*; D016062:Porosity; D054457:Tissue Scaffolds
chemical_list: D018786:Bone Substitutes; D003505:Cyclodextrins; D011108:Polymers; D017886:Durapatite
keywords: bioceramic; bone cancer; cisplatin; cyclodextrin; drug delivery; gentamicin